Sponsor or institution

Clinical trials and research at Shanghai Junshi Bioscience Co., Ltd.

• 17Clinical trials
• 1New in 30 days
• 6Countries

Newest trials

All recruiting trials (17)

• JS212-based therapy for recurrent/metastatic TNBC: as monotherapy or with partners

  This phase 2 study tests JS212 alone or with JS207 or JS001 to see if it helps people with recurrent or metastatic triple-negative breast cancer.

  Recruiting Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality and 30 other locations · NCT07876557

• Glofitamab combo vs Rituximab combo with chemo for relapsed/refractory DLBCL

  This study tests whether glofitamab with chemotherapy (JS203-GemOx) helps patients with relapsed or refractory DLBCL more than rituximab with chemotherapy.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT07808827

• JS212 plus JS111 in EGFR-mutant NSCLC: a Phase II study

  This study tests whether adding JS212 to JS111 is safe and may help control EGFR-mutant advanced NSCLC in patients who progressed after prior EGFR therapy.

  Recruiting at 2 sites Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Shanghai, Shanghai Municipality and 1 other locations · NCT07518160

• JS212 combination treatments for metastatic colorectal cancer.

  This Phase 2 trial will test whether the experimental drug JS212, given with standard chemotherapy (capecitabine with or without bevacizumab or XELOX) and sometimes the immune drug JS207, is safe and active in adults with metastatic colorectal cancer who have not had prior systemic therapy for advanced disease.

  Recruiting Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07503756

• JS212 plus JS001 and 5‑FU for advanced esophageal squamous cell carcinoma

  This will test whether combining JS212 with JS001 and 5‑FU helps people with advanced esophageal squamous cell carcinoma who have not had prior systemic anti‑cancer therapy.

  Recruiting Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT07484724

• JS212 and JS213 alone and in combination for advanced solid tumors

  This trial will test whether JS212 and JS213, given alone or combined with each other or with JS207 or toripalimab, can shrink tumors in people with advanced solid tumors who have progressed after standard treatments.

  Recruiting Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT07480733

• JS212 combo therapy for advanced lung cancer

  This trial tests JS212 with different partners to see if it can help adults with advanced non-small cell or extensive small cell lung cancer.

  Recruiting Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07309276

• JS107 versus doctor‑chosen therapy for CLDN18.2‑positive advanced stomach or gastroesophageal junction cancer after first‑line treatment

  This trial tests whether JS107 works better than doctor‑selected chemotherapy for adults with CLDN18.2‑positive, HER2‑negative advanced stomach or gastroesophageal junction cancer who have already had at least one prior systemic therapy.

  Recruiting at 2 sites Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Hefei, Anhui and 67 other locations · NCT07284134

• JS207 with 9MW2821 or albumin-bound paclitaxel for recurrent or metastatic triple-negative breast cancer

  This trial will try JS207 together with either 9MW2821 or albumin-bound paclitaxel as first-line treatment for people with recurrent or metastatic triple-negative breast cancer who have not had systemic therapy for their advanced disease.

  Recruiting at 14 sites Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Hefei, Anhui and 21 other locations · NCT07045311

• JS207 plus JS007 as first-line treatment for advanced hepatocellular carcinoma

  This trial will test whether JS207 alone or combined with JS007 is safe and effective as a first-line treatment for adults with unresectable, locally advanced, recurrent, or metastatic hepatocellular carcinoma who have not had prior systemic therapy.

  Recruiting at 5 sites Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Hefei, Anhui and 11 other locations · NCT06954467

• JS212 for advanced solid tumors: early safety and initial efficacy

  This trial will test whether the investigational injection JS212 is safe, how the body processes it, and whether it shows early signs of benefit in adults with advanced solid tumors.

  Recruiting Phase 1/2 Shanghai Junshi Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT06888830

• JS207 with or without JS015 plus XELOX chemotherapy for advanced colorectal cancer

  This study will test whether adding the new drug JS207, alone or with JS015, to standard XELOX chemotherapy helps people with advanced MSS/pMMR colorectal cancer respond better or live longer.

  Recruiting at 2 sites Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT06885385

• JS207 (PD‑1/VEGF bispecific) plus chemotherapy for advanced non-squamous NSCLC after TKI failure

  This trial will test whether combining JS207 with pemetrexed and platinum chemotherapy can help people with advanced non-squamous NSCLC who have driver gene changes and have stopped responding to TKIs.

  Recruiting Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Guangzhou, Guangdong · NCT06868836

• AWT020 for safety and tolerability in adults with advanced solid tumors.

  This trial tests whether AWT020 alone or combined with standard chemotherapy is safe and tolerable for adults with advanced solid tumors such as non-small cell lung, colorectal, renal cell carcinoma, and melanoma.

  Recruiting at 6 sites Phase 1 Shanghai Junshi Bioscience Co., Ltd. · Fuzhou, Fujian and 12 other locations · NCT06839105

• Comparing JS004 and Toripalimab to Chemotherapy for Hodgkin Lymphoma

  This study is testing if a new combination of JS004 and Toripalimab can work better than regular chemotherapy for people with Hodgkin lymphoma who haven't responded to previous treatments.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT06170489

• Using toripalimab alone or with tifcemalimab for treating limited-stage small cell lung cancer

  This study is testing if a new combination of two drugs can help people with limited-stage small cell lung cancer feel better after their initial treatment.

  Recruiting at 41 sites Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Harbin, Heilongjiang and 75 other locations · NCT06095583

• Combination treatment for advanced intrahepatic cholangiocarcinoma

  This study is testing if a new combination of medications can help people with advanced liver cancer live longer and feel better compared to standard chemotherapy.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT05342194

Quick answers

How many clinical trials run by Shanghai Junshi Bioscience Co., Ltd. are recruiting right now?

17, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 6 countries. The most sites are in China (17 trials), Georgia (1 trial), Netherlands (1 trial), Spain (1 trial), Taiwan (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 10, Phase 3: 5, Phase 1: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →